496th Edition, February 22, 2022

Trouble Viewing This Email: Click Here

February 22, 2022

FOUNDING MEMBER OF

Maryland Tech Council CEO Marty Rosendale joins Rich Bendis on BioTalk

Marty Rosendale, Chief Executive Officer of the Maryland Tech Council, joins BioTalk to discuss MTCs Programs, Accessing Capital, and Goals for 2022

Listen now on Google https://bit.ly/3LQZNLR, Apple https://apple.co/3H6Aly4, Spotify https://spoti.fi/3LQkZRW, and Amazon https://amzn.to/3sZxuSR, and TuneIn https://bit.ly/3sU6Af0.

How can your BioHealth business benefit from a review by BHI industry experts? Please register for our next Entrepreneur-In-Residence (EIR) day on Mar. 16th and find out.

These free 1:1 virtual sessions are an opportunity to discuss your company with experts in diagnostics, therapeutics, digital health and medical devices. If you’re a growth-stage biohealth company looking for unbiased advice on your pitch deck, commercialization strategy, evidence development or entrepreneurial challenges, our EIRs can help.

To sign-up for any of the EIR dates in 2022, please follow this link.

Montgomery County streamlines zoning to bolster increasingly competitive biotech sector – Washington Business Journal

In a bid to keep and grow its flagship biohealth sector, Montgomery County is dramatically streamlining its regulatory review process for industry players who want to build or expand big lab facilities.

A new zoning text amendment, which the County Council unanimously approved Tuesday, will slash the lab entitlement process time from nearly two years to six months in an effort to “roll out the red carpet” for biotech industry leaders, said Councilman Andrew Friedson, D-District 1, who spearheaded the legislation.

Image: Montgomery County Councilman Andrew Friedson, D-District 1, speaks at a county event to unveil a new zoning process change. The Wednesday gathering was held outside of biotech United Therapeutics' Silver Spring campus. DAN BRENDEL

Ellume / QIAGEN Partnership is Making Tuberculosis Testing More Accessible · BioBuzz

While COVID has most certainly been top-of-mind for companies working to combat infectious disease, we must not forget the other microbes out there that are still cause for concern.

Tuberculosis (TB) is a prime example. Most have heard of this disease, but probably in the context of their history classes. You might be surprised to hear, then, that tuberculosis caused an estimated 1.5 million deaths in 2020, making it second only to COVID as the leading cause of death due to an infectious agent.

Image: https://biobuzz.io

Maryland’s Biotech Tax Incentive Boosts VC Funding with Guaranteed Returns

Maryland’s life sciences ecosystem has become a key hub along the eastern shore of the United States due to its position in infectious disease research and vaccine development and manufacturing. While the state saw an infusion of billions of dollars in government financing in the development of vaccines, Maryland’s Biotechnology Investment Incentive Tax Credit, is a tool that has been used to attract venture capital funding in the state.

The tax credit was established in 2005 to incentivize venture capital investment into the state of Maryland. Since 2016, the most recent year for full data, the state has offered more than $70 million in tax credits to 114 different entities. That, in turn, has generated about $140 million in investments into the state’s life sciences ecosystem, the Baltimore Business Journal reported.

Even old foes can learn sweet new tricks: Cell Host & Microbe

In this issue of Cell Host and Microbe, Haslwanter et al., 2022 present a comprehensive investigation into the molecular and functional basis of 17D vaccine responses and into differences between antibody neutralization of the 17D and related African lineage strains to contemporary Central/South American strains, including the emergent YFV ES-504 strain.

Image: https://www.cell.com

Privia Health Leverages Amalgam Rx’s EHR-Integrated Solutions to Personalize Care | Business Wire

WILMINGTON, Del.–(BUSINESS WIRE)–Amalgam Rx, Inc., a leader in connecting healthcare providers, payers, and life sciences companies through a SaaS-enabled digital marketplace and product platform, and Privia Health Group, Inc., a national physician enablement company, announced a collaboration for multiple EHR-integrated services.

Leveraging Amalgam’s real-time, point-of-care decision support engine, the companies are working together to simplify and enhance the way providers practice value-based care, recruit for clinical trials, and ensure medication safety. Privia Health selected several offerings from Amalgam’s marketplace including:

Image: https://www.businesswire.com

Dean Chang named UMD’s new interim chief innovation officer

The University of Maryland named Dr. Dean Chang as its new interim chief innovation officer and associate vice president for innovation and economic development of the research division, according to an email Monday from the interim and incoming vice presidents for research.

Chang served as founding associate vice president for innovation and entrepreneurship for this university’s Academy for Innovation and Entrepreneurship over the last nine years. In the position, he worked with more than 41,000 students in all 12 of the university’s colleges and schools in innovation, the email said.

Report: NIH SBIR/STTR program supported 99 drugs, numerous successful companies over 25 years | SSTI

The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs of the National Institutes of Health (NIH) supported the development of 99 drugs from 1996-2020 — a total that includes 16 percent of all such treatments that made a “significant” advance over available medicines. This finding is just one of the impacts that the National Academies of Sciences, Engineering and Medicine (NASEM) attributes to the program in a new report.

Ellume – COVID-19 Response

The Ellume COVID-19 Home Test is an over-the-counter, rapid self-test which detects SARS-CoV-2 antigen. The test is suitable for ages 2 years and above for over-the-counter home use in the U.S*. Clinically proven for use for people with and without symptoms, with accurate test results in 15 minutes.

Image: https://www.ellumehealth.com

BioBAT to Receive $50M From City’s Expanded LifeSci NYC Investment | NYCEDC

BROOKLYN, NY—New York City Economic Development Corporation (NYCEDC) announced a $50 million investment in life sciences at BioBAT to expand their lab space as part of the city’s LifeSci NYC initiative. NYCEDC and BioBAT officials toured the space that will receive funding to build new labs at BioBAT located at the Brooklyn Army Terminal.

Image: Photo courtesy of NYCEDC/Tory Williams

In biopharma VC world, what does it mean to take a 'leap'? For Leaps by Bayer, it's 'fewer, but maybe bigger bets' | Fierce Biotech

Sparking innovation at a Big Pharma with a 150-year history can be difficult, so sometimes it takes some outside perspective to get the ball rolling. That's where Leaps by Bayer comes in.

Bayer's venture arm has invested more than $1.5 billion from the balance sheet in the past six years to make bets on disruptive technologies.

Image: Jürgen Eckhardt, M.D., is the head of Leaps by Bayer, the Big Pharma's venture investing arm. (Bayer)

The 2022 Women’s Venture Competition is open for applications until February 28, 2022, 11:59 PM Eastern Time

The AIM-HI Women’s Venture Competition, in its third year, is open for women entrepreneurs! The program provides early-stage funding, coaching, and networking opportunities to women-led oncology startups to address unmet medical needs.

The winning company will receive a total of $1 million in equity investment from AIM-HI and co-investors, subject to due diligence and negotiation. Click here to download the flyer and help spread the word!

About BioHealth Innovation

Contact

Connect